Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Prif Awduron: Ju Li (Awdur), Zhongyuan Zhang (Awdur), Xinhua Wu (Awdur), Jie Zhou (Awdur), Deqian Meng (Awdur), Ping Zhu (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...